Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)
Open Access
- 25 July 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 378 (4), 345-369
- https://doi.org/10.1007/s00210-008-0327-2
Abstract
Rimonabant is an inverse agonist specific for cannabinoid receptors and selective for their cannabinoid-1 (CB1) subtype. Although CB1 receptors are more abundant in the central nervous system, rimonabant has many effects in the periphery, most of which are related to prejunctional modulation of transmitter release from autonomic nerves. However, CB1 receptors are also expressed in, e.g., adipocytes and endothelial cells. Rimonabant inhibits numerous cardiovascular cannabinoid effects, including the decrease of blood pressure by central and peripheral (cardiac and vascular) sites of action, with the latter often being endothelium dependent. Rimonabant may also antagonize cannabinoid effects in myocardial infarction and in hypotension associated with septic shock or liver cirrhosis. In the gastrointestinal tract, rimonabant counteracts the cannabinoid-induced inhibition of secretion and motility. Although not affecting most cannabinoid effects in the airways, rimonabant counteracts inhibition of smooth-muscle contraction by cannabinoids in urogenital tissues and may interfere with embryo attachment and outgrowth of blastocysts. It inhibits cannabinoid-induced decreases of intraocular pressure. Rimonabant can inhibit proliferation of, maturation of, and energy storage by adipocytes. Among the many cannabinoid effects on hormone secretion, only some are rimonabant sensitive. The effects of rimonabant on the immune system are not fully clear, and it may inhibit or stimulate proliferation in several types of cancer. We conclude that direct effects of rimonabant on adipocytes may contribute to its clinical role in treating obesity. Other peripheral effects, many of which occur prejunctionally, may also contribute to its overall clinical profile and lead to additional indications as well adverse events.Keywords
This publication has 293 references indexed in Scilit:
- Cannabinoids in pancreatic cancer: Correlation with survival and painInternational Journal of Cancer, 2007
- Endothelial CB1-receptors limit infarct size through NO formation in rat isolated heartsLife Sciences, 2007
- Pharmacological Inhibition of CB1Cannabinoid Receptor Protects Against Doxorubicin-Induced CardiotoxicityJournal of the American College of Cardiology, 2007
- Anandamide inhibits adhesion and migration of breast cancer cellsExperimental Cell Research, 2005
- Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampusNeuropharmacology, 2005
- Rimonabant: The first therapeutically relevant cannabinoid antagonistLife Sciences, 2005
- Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erectionNeuroscience Letters, 2004
- The Central Cannabinoid Receptor Inactivation Suppresses Endocrine Reproductive FunctionsBiochemical and Biophysical Research Communications, 2001
- Paradoxical action of the cannabinoid WIN 55,212‐2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slicesBritish Journal of Pharmacology, 1997
- 2-Arachidonoylglycerol, a Putative Endogenous Cannabinoid Receptor Ligand, Induces Rapid, Transient Elevation of Intracellular Free Ca2+in Neuroblastoma × Glioma Hybrid NG108-15 CellsBiochemical and Biophysical Research Communications, 1996